167 related articles for article (PubMed ID: 3556307)
1. [Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II].
Sevelda P; Gitsch E; Dittrich C; Haider F; Czerwenka K; Schemper M; Salzer H
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):179-85. PubMed ID: 3556307
[TBL] [Abstract][Full Text] [Related]
2. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the prognostic factors in patients with stage-I and -II ovarian cancer treated by an operation + irradiation variant].
Tarlowska L; Czesnin K; Psikuta M; Romejko M
Vopr Onkol; 1986; 32(3):36-44. PubMed ID: 3962255
[TBL] [Abstract][Full Text] [Related]
4. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
[TBL] [Abstract][Full Text] [Related]
5. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.
Young RC; Walton LA; Ellenberg SS; Homesley HD; Wilbanks GD; Decker DG; Miller A; Park R; Major F
N Engl J Med; 1990 Apr; 322(15):1021-7. PubMed ID: 2181310
[TBL] [Abstract][Full Text] [Related]
7. [Value of prognostic factors in early stage ovarian carcinoma].
Sevelda P
Zentralbl Gynakol; 1996; 118(6):326-9. PubMed ID: 8768008
[TBL] [Abstract][Full Text] [Related]
8. [Developments in the therapy of advanced FIGO III ovarian cancer].
Kuhn W; Jänicke F; Pache L; Hölscher M; Schattenmann G; Schmalfeldt B; Anderl H; Schüle G; Dettmar P; Siewert JR
Geburtshilfe Frauenheilkd; 1993 May; 53(5):293-302. PubMed ID: 8514099
[TBL] [Abstract][Full Text] [Related]
9. [Drug therapy of ovarian carcinoma].
Dittrich C
Wien Med Wochenschr; 1996; 146(1-2):23-34. PubMed ID: 8835492
[TBL] [Abstract][Full Text] [Related]
10. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract][Full Text] [Related]
13. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
Skirnisdottir I; Nordqvist S; Sorbe B
Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
15. [Postoperative radiotherapy of epithelial ovarian cancers].
Kucera H; Sevelda P; Genger H; Weghaupt K
Geburtshilfe Frauenheilkd; 1985 Dec; 45(12):848-52. PubMed ID: 4085759
[TBL] [Abstract][Full Text] [Related]
16. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
18. [Strategy for the ovarian cancer treatment].
Ochiai K
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2454-60. PubMed ID: 8279841
[TBL] [Abstract][Full Text] [Related]
19. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
20. [Epithelial cancer of the ovary. An analysis of a prospective protocol].
Badía JI; Wild R; Barrena N; Mayerson D; Duarte I
Rev Chil Obstet Ginecol; 1991; 56(6):393-402; discussion 402-3. PubMed ID: 1669546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
